Bayer


Bayer’s next rung?

11/10/21 -"Bayer looks a bit shy about announcing the first success in the glyphosate-related battles. Or realistic? We do not know why the company has not made more out of it. From our point of view, the ..."

Pages
84
Language
English
Published on
11/10/21
You may also be interested by these reports :
21/10/21
Roche reported healthy Q3 sales numbers (8% CER growth), with the robust performance in Diagnostics being complemented by a strong contribution from ...

20/10/21
Unlike the broader markets (i.e. STOXX600), Grifols (Buy, Spain) – the global no. three plasma specialist; c.18% market share – has had a tough ride ...

18/10/21
However, given that the on-going strategic investments should result in further leverage build-up, no medium-term dividends are expected. As a ...

14/10/21
The current situation in the CDMO arena looks a bit like an arms race and Lonza seems to have firm plans to be part of it. The recently updated ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO